ComplyRx

Cardiomyopathy & ATTR amyloidosis · Live ClinicalTrials.gov data

Acoramidis (Attruby) clinical trial pipeline

ClinicalTrials.gov lists 9 phase 2–4 trials for acoramidis (Attruby), 4 of them actively recruiting. The next phase 3 primary completion among them is expected Apr 2028. Refreshed daily. Add up to four competitors to compare pipelines side by side.

9

Phase 2–4 trials

6

Phase 3 trials

4

Actively recruiting

Apr 2028

Next phase 3 primary completion

2,283

Participants across trials

Eidos Therapeutics, a BridgeBio company

Lead sponsor by trial count

acoramidis (9)7 active2019–2039
acoramidis
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedWithdrawn
'19
'21
'23
'25
'27
'29
'31
'33
'35
'37
'39
acoramidis
ATTRibute-CMP3
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMP3
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)P3
AG10P3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantP3
ATTR-CMP4
ACO-SWITCHP4
ASCEND-ATTRP4
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)P3

Upcoming readouts

7 ahead · acoramidis

Select a trial to load its full ClinicalTrials.gov record.

Key acoramidis trials

Top 9 of the 9 registered phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

TrialTitlePhaseStatusPrimary completion
NCT07298044ACO-SWITCH: A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants Wi…Phase 4RecruitingJul 2027
NCT07306949ATTR-CM: Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Card…Phase 4RecruitingMar 2028
NCT07695701ASCEND-ATTR: Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisPhase 4RecruitingAug 2030
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptom…Phase 3RecruitingOct 2031
NCT04988386AG10: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsPhase 3Active, not recruitingApr 2028
NCT07116473To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagn…Phase 3Not yet recruitingNov 2037
NCT03860935ATTRibute-CM: Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyPhase 3CompletedMay 2023
NCT04622046A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMPhase 3CompletedNov 2023
NCT04882735Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy …Phase 3WithdrawnSept 2026

Track acoramidis with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track acoramidis

Related drug pipelines

Compare acoramidis vs mavacamtenCompare acoramidis vs aficamten

FAQ

How many clinical trials are running for acoramidis?
ClinicalTrials.gov currently lists 9 phase 2–4 acoramidis trials: 0 phase 2, 6 phase 3, and 3 phase 4. 4 are actively recruiting.
Are there clinical trials for Attruby?
Attruby is the brand name for acoramidis, so acoramidis trials on ClinicalTrials.gov cover it. ClinicalTrials.gov currently lists 9 phase 2–4 acoramidis trials: 0 phase 2, 6 phase 3, and 3 phase 4. 4 are actively recruiting.
Where does this data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare acoramidis against other drugs?
Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.